10.08.2011 (286 Days Ago)
| Title | BHRT Bioheart, Inc. | ||
| Country | United States |
| • | To elect nine members to the Company’s Board of Directors to hold office until the next annual meeting of shareholders or until their successors are duly elected and qualified; | |
| • | To consider and vote upon a proposal to approve of and ratify the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2008; | |
| • | To consider and vote upon a proposal to amend the Company’s Articles of Incorporation to increase the number of authorized shares of the common stock of the Company from 50,000,000 shares to 75,000,000 shares; | |
| • | To consider and vote upon a proposal to establish the Bioheart Omnibus Equity Compensation Plan; and | |
| • | To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. |
ACTC
http://findarticles.com/p/articles/mi_m0EI...24/ai_n20512497
BHRT
http://biz.yahoo.com/e/071116/bhrt10-q.html
http://www.tissuegenesis.com/New%20Victories.pdf
This is getting interesting.
Adult Muscle Stem Cells – Myoblasts
Two studies show encouraging promise in using adult muscle stem cells derived from a patient’s own thigh tissue to treat advanced heart failure. Dr. Warren Sherman of Columbia University and Dr. Nabil Dib of the University of California, San Diego presented data on this approach, which has been used to treat over 300 patients in clinical trials since 2000. The procedure involves delivering cells via a thin plastic tube with an injection needle on the tip, inserted in the patients groin and directed to the inside of the heart in order to grow new muscle in the heart’s scar tissue. Dr. Sherman presented final one year results of the MYOHEART trial sponsored by Bioheart, Inc., in which 83 percent of patients treated in this manner with adult muscle stem cells, also known as myoblasts, improved. Only 17 percent remained unchanged or worsened. “Eighty-three percent of myoblast treated heart failure patients improving compares favorably with the 369 patient 'gold-standard' bi-ventricular pacer study where approximately 55 percent of the 187 treated patients showed improvement in NYHA Class or quality of life score as compared to only 40 percent improvement for the 182 control patients who were on drug therapy alone,” stated Dr. Sherman. A separate study led by Dr. Nabil Dib, sponsored by Advanced Cell Therapy, Inc., showed similar results, and both groups have now moved onto Phase II/III placebo controlled trials currently in the process of enrolling together more than 495 patients. The procedure (16 injections in a cardiac cath lab) takes about 45 minutes.
=========================================
Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On August 6, 2008, we amended our Articles of Incorporation to increase the number of authorized shares of our common stock from 50 million to 75 million shares (the "Amendment"). The Amendment was approved by our shareholders at our Annual Meeting of Shareholders held on July 30, 2008. Item 9.01 Financial Statements and Exhibits
(d) Exhibits
3.1 Articles of Amendment to the Articles of Incorporation of the registrant
BHRT Security Details
Share Structure
| Market Value1 | $3,095,209 | a/o Aug 09, 2011 |
| Shares Outstanding | 42,989,019 | a/o May 19, 2011 |
| Float | Not Available | |
| Authorized Shares | Unlimited | a/o |
| Par Value | 0.001 |
|
Company Officers
|
- There are no comments yet
|
|